$TNDM earnings report

Tandem Diabetes Care Announces Third Quarter 2026 Financial Results. AlphAI read Tandem Diabetes Care's Third Quarter 2026 filing as solid. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readTNDM · Third Quarter 2026 · ended September 30, 2026

Tandem Diabetes Care Announces Third Quarter 2026 Financial Results

✓Solid quarter

Worldwide sales increased 14% to $283.7 million, gross margin rose to 57%, operating loss narrowed to $2.4 million, and adjusted EBITDA increased to $18.0 million. The company reaffirmed its 2026 sales, gross-margin and adjusted EBITDA-margin outlook.

United States pump sales, three months ended September 30
$83.4M
(2)% y/y
Gross margin · GAAP
57%
up 270 basis points y/y
EPS · GAAP
$(0.10)
Year ending December 31, 2026 outlook
Sales are estimated to be approximately $1.065 billion to $1.085 billion
GM approximately 56% to 57% of sales

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Sales, three months ended September 30GAAP$283.7M–14%
Cost of sales, three months ended September 30GAAP123,268––
Gross profit, three months ended September 30GAAP$160.4M––
Gross margin, three months ended September 30GAAP57%–up 270 basis points
Selling, general and administrative expense, three months ended September 30GAAP113,945––
Research and development expense, three months ended September 30GAAP48,846––
Total operating expenses, three months ended September 30GAAP162,791––
Operating loss, three months ended September 30GAAP−$2.37M––
GAAP operating margin, three months ended September 30GAAP(1)%–improved 830 basis points
Total other income (expense), net, three months ended September 30GAAP−$5.32M––
Loss before income taxes, three months ended September 30GAAP−$7.69M––
Income tax expense (benefit), three months ended September 30GAAP−$608K––
Net loss, three months ended September 30GAAP−$7.08M––
Net loss per share, basic and diluted, three months ended September 30GAAP$(0.10)––
Weighted average shares used to compute basic and diluted net loss per share, three months ended September 30GAAP69,650––
Adjusted EBITDA, three months ended September 30non-GAAP$18.04M––
Adjusted EBITDA margin, three months ended September 30non-GAAP6 %––
GAAP cash used in operating activities, three months ended September 30GAAP−$819K––
Capital expenditures, three months ended September 30other−$4.69M––
Free cash flow, three months ended September 30non-GAAP−$5.51M––
Sales, nine months ended September 30GAAP$785.5M–8%
Gross profit, nine months ended September 30GAAP$442.0M––
Operating loss, nine months ended September 30GAAP−$33.59M––
Net loss, nine months ended September 30GAAP−$48.65M––
Net loss per share, basic and diluted, nine months ended September 30GAAP$(0.70)––
Adjusted EBITDA, nine months ended September 30non-GAAP$27.18M––
Adjusted EBITDA margin, nine months ended September 30non-GAAP3 %––
GAAP cash used in operating activities, nine months ended September 30GAAP−$24.39M––
Free cash flow, nine months ended September 30non-GAAP−$39.4M––

Segments

SegmentRevenueq/qy/y
United States pump sales, three months ended September 30Pump sales$83.38M–(2)%
United States supplies and other sales, three months ended September 30Supplies and other sales$107.7M–19%
Total Sales in the United States, three months ended September 30U.S. shipments were nearly 23,000 pumps, compared to more than 20,000 pumps.$191.0M–9%
International pump sales, three months ended September 30Pump sales$31.57M–25%
International supplies and other sales, three months ended September 30Supplies and other sales$61.07M–26%
Total International Sales, three months ended September 30International shipments were nearly 11,000 pumps, compared to more than 9,000 pumps. International sales increased 27% in constant currency.$92.64M–26%
United States pump sales, nine months ended September 30Pump sales$244.3M–1%
United States supplies and other sales, nine months ended September 30Supplies and other sales$286.9M–13%
Total Sales in the United States, nine months ended September 30Sales by geography$531.2M–7%
International pump sales, nine months ended September 30Pump sales$95.71M–17%
International supplies and other sales, nine months ended September 30Supplies and other sales$158.6M–8%
Total International Sales, nine months ended September 30International sales increased 9% in constant currency.$254.3M–12%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Year ending December 31, 2026 outlook

  • RevenueSales are estimated to be approximately $1.065 billion to $1.085 billion
  • Gross marginapproximately 56% to 57% of sales
  • NoteU.S. sales of approximately $730 million to $745 million
  • NoteInternational sales of approximately $335 million to $340 million
  • NoteAdjusted EBITDA margin is estimated to be approximately 5% to 6% of sales
  • NoteNon-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $85 million.
  • NoteApproximately $65 million non-cash, stock-based compensation expense
  • NoteApproximately $20 million depreciation and amortization expense

What drove it

  • Worldwide sales increased 14% to $283.7 million.
  • International sales increased 26% to $92.6 million and increased 27% in constant currency.
  • U.S. supplies and other sales increased 19% to $107,664.
  • International supplies and other sales increased 26% to $61,070.
  • Gross margin was 57%, compared to 54%.
  • The pay-as-you-go reimbursement model resulted in 15% of U.S. sales through the pharmacy channel.
  • Pharmacy formulary coverage increased to approximately 50% of U.S. lives.
  • The company expanded t:slim X2 compatibility with the Abbott FreeStyle Libre 3 Plus Sensor to 11 international markets and announced international availability of Tandem Mobi in 12 countries.

Concerns

  • U.S. pump sales were $83,381, compared to $84,785, a decline of (2)%.
  • The company reported a GAAP net loss of $(7,085) and a GAAP operating loss of $(2,369) for the third quarter.
  • Third-quarter GAAP cash used in operating activities was $(819), and non-GAAP free cash flow was $(5,506).
  • Nine-month non-GAAP free cash flow was $(39,400).
  • Convertible senior notes, net - long-term were $603,388 as of September 30, 2026.

What to watch

  • Execution against full-year sales guidance of approximately $1.065 billion to $1.085 billion.
  • U.S. sales guidance of approximately $730 million to $745 million and international sales guidance of approximately $335 million to $340 million.
  • Full-year gross-margin guidance of approximately 56% to 57% of sales.
  • Full-year adjusted EBITDA-margin guidance of approximately 5% to 6% of sales.
  • Adoption of the pay-as-you-go reimbursement model and pricing and transition assumptions for the U.S. pharmacy channel.
  • Expansion of international direct operations and availability of Tandem Mobi in 12 countries.

Balance sheet and cash flow

  • Cash, cash equivalents and short-term investments were $443,082 as of September 30, 2026, compared to $292,666 as of December 31, 2025.
  • Convertible senior notes, net - long-term were $603,388 as of September 30, 2026, compared to $310,036 as of December 31, 2025.
  • Total assets were $1,159,494 as of September 30, 2026, compared to $881,112 as of December 31, 2025.
  • Total liabilities were $1,024,407 as of September 30, 2026, compared to $725,942 as of December 31, 2025.
  • Total stockholders' equity was $135,087 as of September 30, 2026, compared to $155,170 as of December 31, 2025.
  • Nine-month GAAP cash used in operating activities was $(24,395), compared to $(19,510).
  • Nine-month capital expenditures were $(15,005), compared to $(13,263).
  • Nine-month non-GAAP free cash flow was $(39,400), compared to $(32,773).

Analysis

Tandem reported third-quarter worldwide sales of $283.7 million, up 14% from $249.3 million. U.S. sales increased 9% to $191.0 million, while international sales increased 26% to $92.6 million and 27% in constant currency. The geographic mix favored international growth, while U.S. supplies and other sales increased 19% and U.S. pump sales declined (2)% to $83,381.

Management, verbatim

Tandem’s third-quarter performance demonstrates that our strategy is delivering results. We are expanding access to Tandem’s life-changing technology, strengthening our business model, advancing our pipeline and driving greater operating efficiency, creating a stronger foundation for sustainable, profitable growth.

John Sheridan, president and chief executive officer

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for reported financial metrics
  • Non-GAAP earnings or loss per share
  • GAAP or non-GAAP tax-rate guidance
  • Operating-expense guidance
  • Share repurchases
  • Dividend declaration or payment
  • Prior financial guidance for comparison
  • CFO commentary

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readTNDM · Second Quarter 2026 · ended June 30, 2026

Tandem Diabetes Care Announces Second Quarter 2026 Financial Results

✓Solid quarter

Worldwide sales increased 6% to $254.6 million, gross margin increased to 57% from 52%, and adjusted EBITDA was positive at $6.4 million. The company reaffirmed its 2026 sales, gross-margin, and adjusted EBITDA-margin guidance, while reducing estimated non-cash charges.

United States sales, three months ended June 30, 2026
$179M
5% y/y
Gross margin · GAAP
57%
up 460 basis points y/y
EPS · GAAP
$ (0.31)
Year ending December 31, 2026 outlook
Sales are estimated to be approximately $1.065 billion to $1.085 billion
GM approximately 56% to 57% of sales

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Sales, three months ended June 30, 2026GAAP$254.6M–6%
Sales, six months ended June 30, 2026GAAP$501.8M–6%
Cost of sales, three months ended June 30, 2026GAAP$109.8M––
Cost of sales, six months ended June 30, 2026GAAP$220.2M––
Gross profit, three months ended June 30, 2026GAAP$144.8M––
Gross margin, three months ended June 30, 2026GAAP57%–up 460 basis points
Gross profit, six months ended June 30, 2026GAAP$281.6M––
Selling, general and administrative expense, three months ended June 30, 2026GAAP$111.6M––
Selling, general and administrative expense, six months ended June 30, 2026GAAP$219.8M––
Research and development expense, three months ended June 30, 2026GAAP$46.93M––
Research and development expense, six months ended June 30, 2026GAAP$92.97M––
Acquired in-process research and development expenses, six months ended June 30, 2026GAAP—––
Litigation and settlement expense, three months ended June 30, 2026GAAP—––
Total operating expenses, three months ended June 30, 2026GAAP$158.6M––
Total operating expenses, six months ended June 30, 2026GAAP$312.8M––
Operating loss, three months ended June 30, 2026GAAP−$13.79M––
GAAP operating margin, three months ended June 30, 2026GAAP(5)%–improved 800 basis points
Non-GAAP operating loss, three months ended June 30, 2026non-GAAP−$13.79M––
Non-GAAP operating margin, three months ended June 30, 2026non-GAAP(5)%––
Operating loss, six months ended June 30, 2026GAAP−$31.23M––
Non-GAAP operating loss, six months ended June 30, 2026non-GAAP−$31.23M––
Net loss, three months ended June 30, 2026GAAP−$21.17M––
Non-GAAP net loss, three months ended June 30, 2026non-GAAP−$21.17M––
Net loss per share - basic and diluted, three months ended June 30, 2026GAAP$ (0.31)––
Net loss, six months ended June 30, 2026GAAP−$41.56M––
Net loss per share - basic and diluted, six months ended June 30, 2026GAAP$ (0.60)––
Adjusted EBITDA, three months ended June 30, 2026non-GAAP$6.42M––
Adjusted EBITDA margin, three months ended June 30, 2026non-GAAP3 %––
Adjusted EBITDA, six months ended June 30, 2026non-GAAP$9.15M––
Adjusted EBITDA margin, six months ended June 30, 2026non-GAAP2 %––
GAAP cash used in operating activities, three months ended June 30, 2026GAAP−$34.62M––
Non-GAAP free cash flow, three months ended June 30, 2026non-GAAP−$38.67M––
GAAP cash used in operating activities, six months ended June 30, 2026GAAP−$23.58M––
Capital expenditures, six months ended June 30, 2026other(10,318)––
Non-GAAP free cash flow, six months ended June 30, 2026non-GAAP−$33.89M––

Segments

SegmentRevenueq/qy/y
United States sales, three months ended June 30, 2026Pump sales were $ 83,002, compared to $ 85,467, while supplies and other sales were $ 96,290, compared to $ 84,742.$179.3M–5%
International sales, three months ended June 30, 2026Pump sales were $ 31,650, compared to $ 26,404, while supplies and other sales were $ 43,618, compared to $ 44,065. International sales increased 6% in constant currency.$75.27M–7%
United States pump sales, three months ended June 30, 2026U.S. shipments were more than 22,000 pumps, compared to approximately 21,000 pumps.$83.00M–(3)%
United States supplies and other sales, three months ended June 30, 2026Supplies and other sales increased from $ 84,742.$96.29M–14%
International pump sales, three months ended June 30, 2026International shipments were approximately 11,000 pumps, compared to approximately 9,000 pumps.$31.65M–20%
International supplies and other sales, three months ended June 30, 2026Supplies and other sales were compared with $ 44,065.$43.62M–(1)%
United States sales, six months ended June 30, 2026Pump sales were $ 160,943 and supplies and other sales were $ 179,192.$340.1M–6%
International sales, six months ended June 30, 2026Pump sales were $ 64,135 and supplies and other sales were $ 97,511. International sales constant-currency change was —%.$161.6M–5%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Year ending December 31, 2026 outlook

  • RevenueSales are estimated to be approximately $1.065 billion to $1.085 billion
  • Gross marginapproximately 56% to 57% of sales
  • NoteU.S. sales of approximately $730 million to $745 million
  • NoteInternational sales of approximately $335 million to $340 million
  • NoteAdjusted EBITDA margin is estimated to be approximately 5% to 6% of sales
  • NoteNon-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $85 million, a reduction from $100 million
  • NoteApproximately $65 million non-cash, stock-based compensation expense, a reduction from $80 million
  • NoteApproximately $20 million depreciation and amortization expense

What drove it

  • Worldwide pump shipments were more than 33,000 pumps, including 22,000 pumps in the U.S.
  • The pay-as-you-go reimbursement model accounted for 10% of U.S. sales through the pharmacy channel.
  • The company submitted a 510(k) with the FDA for Tandem Mobi tubeless capability.
  • Tandem introduced Dexcom G7 15-day sensor compatibility for t:slim X2 and Tandem Mobi in the U.S.
  • The company launched t:slim X2 compatibility with the Abbott FreeStyle Libre 3 Plus Sensor in four European markets and began the international commercial rollout for Tandem Mobi.

Concerns

  • The company reported a GAAP net loss of $ (21,168) and GAAP cash used in operating activities of $ (34,623) for the three months ended June 30, 2026.
  • U.S. pump sales were $ 83,002, a (3)% change from the prior-year period.
  • Non-GAAP free cash flow was $ (38,673) for the three months ended June 30, 2026.
  • Convertible senior notes, net - long-term increased to $ 602,577 as of June 30, 2026 from $ 310,036 as of December 31, 2025.

What to watch

  • Achievement of sales estimated to be approximately $1.065 billion to $1.085 billion for the year ending December 31, 2026.
  • Delivery of gross margin estimated to be approximately 56% to 57% of sales and adjusted EBITDA margin estimated to be approximately 5% to 6% of sales.
  • U.S. sales of approximately $730 million to $745 million and international sales of approximately $335 million to $340 million.
  • Adoption of the pay-as-you-go reimbursement model in the U.S. and the initiation of international direct operations.
  • Progress of the Tandem Mobi tubeless capability 510(k) submission and the international commercial rollout for Tandem Mobi.

Balance sheet and cash flow

  • Cash, cash equivalents and short-term investments were $ 455,996 as of June 30, 2026, compared to $ 292,666 as of December 31, 2025.
  • Convertible senior notes, net - long-term were $ 602,577 as of June 30, 2026, compared to $ 310,036 as of December 31, 2025.
  • Total assets were $ 1,154,202 as of June 30, 2026, compared to $ 881,112 as of December 31, 2025.
  • Total liabilities were $ 1,023,814 as of June 30, 2026, compared to $ 725,942 as of December 31, 2025.
  • Total stockholders’ equity was $ 130,388 as of June 30, 2026, compared to $ 155,170 as of December 31, 2025.
  • Capital expenditures were (4,050) for the three months ended June 30, 2026, compared to (6,207).

Analysis

Second-quarter worldwide sales were $254.6 million, up 6% from $240.7 million, with 5% constant-currency sales growth. U.S. sales increased 5% to $179.3 million and international sales increased 7% to $75.3 million. The release reported more than 33,000 worldwide pump shipments, including 22,000 in the U.S., while the pay-as-you-go reimbursement model represented 10% of U.S. sales through the pharmacy channel.

The sales mix showed differing product trends. U.S. pump sales were $83.0 million, down 3%, while U.S. supplies and other sales were $96.3 million, up 14%. International pump sales were $31.7 million, up 20%, while international supplies and other sales were $43.6 million, down 1%. International sales increased 6% in constant currency.

Profitability improved materially. Gross profit was $144.8 million and gross margin was 57%, compared with gross profit of $125.9 million and gross margin of 52% in the prior-year quarter. GAAP operating loss narrowed to $13.8 million from $51.8 million, and adjusted EBITDA was $6.4 million compared with negative $1.8 million. The prior-year quarter included a $20.0 million litigation settlement expense.

The company remained loss-making and free cash flow was negative. GAAP net loss was $21.2 million, while GAAP cash used in operating activities was $34.6 million and non-GAAP free cash flow was $38.7 million negative. Cash, cash equivalents and short-term investments were $456.0 million at June 30, 2026, while convertible senior notes, net - long-term were $602.6 million.

Tandem reaffirmed its 2026 sales, U.S. sales, international sales, gross-margin, and adjusted EBITDA-margin guidance. It also reduced estimated non-cash charges included in cost of goods sold and operating expenses to approximately $85 million from $100 million, including approximately $65 million of stock-based compensation expense from $80 million. Strategic progress included the Tandem Mobi tubeless capability 510(k) submission, new sensor compatibility, and the start of the international commercial rollout for Tandem Mobi.

Management, verbatim

Our second quarter results reflect meaningful progress across the priorities we set for 2026. We are seeing tangible evidence that our strategy is gaining traction and the momentum we are building reinforces our confidence in Tandem’s ability to drive broader customer impact, strengthen our financial performance and create long-term value.

John Sheridan, president and chief executive officer

Not in the filing

stated, not guessed
  • Prior-quarter comparisons were not reported.
  • No prior outlook section was provided, so comparisons of actual results with prior guidance are unavailable.
  • Dividend and share-repurchase activity were not reported.
  • A forward operating-expenses guidance figure was not reported.
  • A forward tax-rate guidance figure was not reported.
  • Tax rate was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about TNDM earnings dates

When is Tandem Diabetes Care's next earnings date?
AlphAI has no date for TNDM yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.